Cobamamide and Central nervous system lesion - a phase IV clinical study of FDA data

Summary:

Central nervous system lesion is reported as a side effect among people who take Cobamamide (dibencozide), especially for people who are male, 50-59 old, also take Baclofen, and have Secondary progressive multiple sclerosis.

The phase IV clinical study analyzes which people have Central nervous system lesion when taking Cobamamide. It is created by eHealthMe based on reports of 1,046 people who have side effects when taking Cobamamide from the FDA, and is updated regularly.

What is Cobamamide?

Cobamamide has active ingredients of dibencozide. eHealthMe is studying from 1,046 Cobamamide users. Check the latest studies of Cobamamide.

What is Central nervous system lesion?

Central nervous system lesion (an abnormality in tissue of brain or spinal cord) is found to be associated with 779 drugs and 824 conditions by eHealthMe. Check the latest studies of Central nervous system lesion.

On Jul, 20, 2026

1,046 people reported to have side effects when taking Cobamamide.
Among them, 44 people (4.21%) have Central nervous system lesion.

Could Cobamamide cause Central nervous system lesion?

Among these 44 people:

What is the gender of people who have Central nervous system lesion when taking Cobamamide? *

female: 2.56 %
male: 97.44 %

What is the age of people who have Central nervous system lesion when taking Cobamamide? *

What are other drugs people take besides Cobamamide? *

What are other side effects people have besides Central nervous system lesion? *

Hypoaesthesia (reduced sense of touch or sensation): 44 people, 100.00%
Urination - Excessive At Night: 43 people, 97.73%
Stress And Anxiety: 43 people, 97.73%
Bradycardia (abnormally slow heart action): 43 people, 97.73%
Dizziness: 43 people, 97.73%
Erection Problems: 43 people, 97.73%
Fall: 43 people, 97.73%
Gait Spastic: 43 people, 97.73%
Hypertonic Bladder (bladder-storage function that causes a sudden urge to urinate): 43 people, 97.73%
Insomnia (sleeplessness): 43 people, 97.73%

What are the existing conditions these people have? *

Secondary Progressive Multiple Sclerosis (a stage of ms which comes after relapsing remitting ms in many cases): 43 people, 97.73%
Multiple Sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 1 person, 2.27%

* Approximation only. Some reports may have incomplete information.

Do you take Cobamamide and have Central nervous system lesion?

- Check whether Central nervous system lesion is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Cobamamide:

Cobamamide (1,046 reports)

Browse all side effects of Cobamamide:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Central nervous system lesion:

Central nervous system lesion (780 drugs)

Browse all the conditions that are associated with Central nervous system lesion:

Central nervous system lesion (824 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on dibencozide (the active ingredients of Cobamamide) and Cobamamide (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.